Clinical Trial Search

Primary: Combined Clinical Thromboembolic or Hemorrhagic Event, Death or Silent Cerebral Thromboemboli — 9; 11 Participants

Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score

Primary: The Modified Rankin Scale Score — 3.9; 3.4; 4.0; 4.4 units on a scale

Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006

Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities

Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants

Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants

Primary: Completion of Clinical Follow-up as a Measure of Feasibility — 20; 18 participants

Primary: Percentage of Participants With Successful Revascularization — 98.0 Percentage of participants

Primary: Clot Specimen Histology — 373; 12 Count of specimen

Primary: Number of Participants With a Composite Endpoint of Fatal Stroke, Recurrent Ischemic Stroke, or TIA — 7; 12 Participants

Primary: Successful Revascularization Measured Using Modified Thrombolysis in Cerebrovascular Infarction (mTICI Inclusive of the 2c Rating) — 182 Participants

Primary: Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset — 3; 2; 22; 99 participants — p=0.053

Primary: The Number of Patients Who Experience Symptomatic Intracerebral Hemorrhage (sICH). — 1 participants

Primary: Number of Serious Adverse Events Within 30 Days Post-Index Procedure — 0 participants

Primary: The Rate of AF Through 12 Months in Subjects With a Recent Ischemic Stroke of Presumed Known Origin. — 12.5; 1.8 percentage of participants — p=<0.001

Primary: 90-day Global Disability Assessed Via the Blinded Evaluation of Modified Rankin Score (mRS). — 17; 8; 25; 10 Participants

Primary: Transcranial Doppler(TCD) Microembolic Signals During Surgical Aortic Valve Replacement Surgery — 354 units on a scale

Primary: Degree of Disability/Dependence as Measured by the Modified Rankin Scale (mRS) Score — 4; 5 scores on a scale

Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants

Primary: Attendance Rate — 8 Participants

Primary: Revascularization Status — 92 percentage of subjects TICI 2 or >

Primary: Primary Efficacy Endpoint — 54; 76 participants

Primary: Reduction in Median Total New Lesion Volume in Protected Territories Between Test and Control Arms as Assessed by DW-MRI at Day 2-7 Post-procedure. — 109.1; 174 mm3

Primary: Change in Behavioral Intent to Call 911 — 2.1; 0.4 units on a scale

Primary: Composite of Recurrent Nonfatal Ischemic Stroke, Fatal Ischemic Stroke, or Early Death After Randomization — 9; 16 Participants — p=0.08

Primary: Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) — 100; 88 minutes

Primary: Modified Rankin Score (mRS) Between Favorable CIS Group Versus Poor CIS Group. — 22; 1; 23; 10 Participants

Primary: The Rate of Stroke Through 72 Hours Post TAVR Procedure or Discharge (Whichever Comes First) — 34; 43 Participants

Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale